EC0652 Prostate Cancer Molecular Imaging*
Designed to non-invasively identify tumors that express prostate-specific membrane antigen (PSMA) receptors
EC0652 is a PSMA-targeted molecular imaging agent that is being developed to non-invasively identify tumors that express PSMA receptors.
EC0652 is currently being evaluated in a Phase 0 trial for patients with advanced prostate cancer.
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.